Cargando…

Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up

INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bravo, Francisco, Macpherson, Jamie A., Slack, Emma, Patuto, Nicolas, Cahenzli, Julia, McCoy, Kathy D., Macpherson, Andrew J., Juillerat, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886452/
https://www.ncbi.nlm.nih.gov/pubmed/33735154
http://dx.doi.org/10.14309/ctg.0000000000000298
_version_ 1783651796961460224
author Bravo, Francisco
Macpherson, Jamie A.
Slack, Emma
Patuto, Nicolas
Cahenzli, Julia
McCoy, Kathy D.
Macpherson, Andrew J.
Juillerat, Pascal
author_facet Bravo, Francisco
Macpherson, Jamie A.
Slack, Emma
Patuto, Nicolas
Cahenzli, Julia
McCoy, Kathy D.
Macpherson, Andrew J.
Juillerat, Pascal
author_sort Bravo, Francisco
collection PubMed
description INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). METHODS: Patients with IBD were classified according to the shedding of an L-selectin (CD62L) from the surface of their granulocytes in whole blood. CD62L shedding was quantified by flow cytometry before and after drug administration. A clinical data collection from June 2012 to August 2017 with blinded IFX management was aimed at validating the long-term predictive value of this test. RESULTS: Among 33 patients with IBD (17 Crohn's disease and 5 ulcerative colitis), 22 were predicted functional responders (PFR) and 11 were predicted as nonresponders (NR) according to the in vitro test. Five years after study initiation, 72% of PFR were still treated with IFX (vs 27% in the NR group; P < 0.05), with a median time spent under IFX of 45 vs 12 months (P = 0.019), respectively. Thirty-five medicosurgical events occurred with a median time to first event of 3 vs 30 months (P = 0.023), respectively. Our assay was the best independent predictor of staying long term on IFX (P = 0.056). DISCUSSION: An assay-based in vitro test for functional blockade of TNFα (CD62L shedding) provides an excellent long-term (at 3–5 years) independent predictor of durable use of IFX in patients with IBD. Testing patients could personalize decision making to significantly reduce costs and risk of adverse events and complications. [Image: see text]
format Online
Article
Text
id pubmed-7886452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-78864522021-02-17 Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up Bravo, Francisco Macpherson, Jamie A. Slack, Emma Patuto, Nicolas Cahenzli, Julia McCoy, Kathy D. Macpherson, Andrew J. Juillerat, Pascal Clin Transl Gastroenterol Article INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). METHODS: Patients with IBD were classified according to the shedding of an L-selectin (CD62L) from the surface of their granulocytes in whole blood. CD62L shedding was quantified by flow cytometry before and after drug administration. A clinical data collection from June 2012 to August 2017 with blinded IFX management was aimed at validating the long-term predictive value of this test. RESULTS: Among 33 patients with IBD (17 Crohn's disease and 5 ulcerative colitis), 22 were predicted functional responders (PFR) and 11 were predicted as nonresponders (NR) according to the in vitro test. Five years after study initiation, 72% of PFR were still treated with IFX (vs 27% in the NR group; P < 0.05), with a median time spent under IFX of 45 vs 12 months (P = 0.019), respectively. Thirty-five medicosurgical events occurred with a median time to first event of 3 vs 30 months (P = 0.023), respectively. Our assay was the best independent predictor of staying long term on IFX (P = 0.056). DISCUSSION: An assay-based in vitro test for functional blockade of TNFα (CD62L shedding) provides an excellent long-term (at 3–5 years) independent predictor of durable use of IFX in patients with IBD. Testing patients could personalize decision making to significantly reduce costs and risk of adverse events and complications. [Image: see text] Wolters Kluwer 2021-02-15 /pmc/articles/PMC7886452/ /pubmed/33735154 http://dx.doi.org/10.14309/ctg.0000000000000298 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Bravo, Francisco
Macpherson, Jamie A.
Slack, Emma
Patuto, Nicolas
Cahenzli, Julia
McCoy, Kathy D.
Macpherson, Andrew J.
Juillerat, Pascal
Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title_full Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title_fullStr Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title_full_unstemmed Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title_short Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
title_sort prospective validation of cd-62l (l-selectin) as marker of durable response to infliximab treatment in patients with inflammatory bowel disease: a 5-year clinical follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886452/
https://www.ncbi.nlm.nih.gov/pubmed/33735154
http://dx.doi.org/10.14309/ctg.0000000000000298
work_keys_str_mv AT bravofrancisco prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT macphersonjamiea prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT slackemma prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT patutonicolas prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT cahenzlijulia prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT mccoykathyd prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT macphersonandrewj prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup
AT juilleratpascal prospectivevalidationofcd62llselectinasmarkerofdurableresponsetoinfliximabtreatmentinpatientswithinflammatoryboweldiseasea5yearclinicalfollowup